Personalized Optimization of Systematic Prostate Biopsy

Recruiting now · Not applicable

Conditions studied: Prostate Adenocarcinoma

In brief

Targeted biopsy combined systematic biopsy is the gold standard for diagnosis of prostate cancer. Excessive cores in systematic biopsy increases the risk of puncture trauma, bleeding and infection. On the basis of establishing a model with DRS stratification to reduce the cores of systematic biopsy, we propose the (12 cores -x) model innovatively. We hope that through this prospective study to verify the efficacy of the model and provide patients with a new biopsy model with high accuracy and fewer complications. In this study, patients with suspected prostate cancer were randomly divided into two groups. Experimental group received targeted biopsy combined personalized systematic biopsy, and the control group received systematic biopsy .The differences of the detection rate of Prostate cancer between the two groups were compared.

Key facts

Study ID
NCT05998278
Run by
Fujian Medical University Union Hospital
People needed
330
Starts
2023-08-23
Expected to finish
2025-12-30
Last updated by the study team
2025-12-18

Who can join

Age: 50 and older, up to 95. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.